Physician profile
Curtis E Clark
NPI 1538117528
$1,647.58
in general payments reported to CMS, 2019-2025
21 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.90 · 2020: $13.43 · 2022: $17.05 · 2023: $30.24 · 2024: $137 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $357.29 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $210.42 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $147.55 | 2025 | |
| Glaxosmithkline, LLC. | $106.08 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $105.78 | 2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.23 | 2024-2025 | Jardiance |
| Pfizer INC. | $98.93 | 2025 | |
| Novo Nordisk INC | $85.48 | 2019-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $76.46 | 2025 | Gemtesa |
| Abbvie INC. | $72.32 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $47.72 | 2025 | Rexulti |
| Astellas Pharma US INC | $41.78 | 2020-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $41.76 | 2022-2024 | Gvoke Hypopen |
| Abbott Laboratories | $24.74 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $24.58 | 2025 | The Cologuard Plus Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $21.91 | 2025 | |
| Intuitive Surgical, INC. | $18.95 | 2024 | |
| Philips North America LLC | $15.78 | 2024 | (Cm9) Amb Mon & Diag Und |
| Janssen Pharmaceuticals, INC | $15.58 | 2019 | |
| Rti Surgical, INC | $15.51 | 2023 | |
| Abiomed | $14.73 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.